Credit Agricole S A Trims Position in Agilent Technologies, Inc. $A

Key Points

• Credit Agricole S A has decreased its stake in Agilent Technologies, Inc. by 33.8%, representing ownership of 105,773 shares valued at approximately $12.37 million at the end of the last quarter.
• Vanguard Group Inc. has slightly increased its holdings in Agilent Technologies by 0.7%, now owning about 33.4 million shares valued at around $3.91 billion.
• Agilent Technologies' stock has received a consensus rating of "Moderate Buy" from analysts, with a target price of $139.77 following various changes in price objectives from multiple brokerage firms.

Credit Agricole S A lessened its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 33.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,773 shares of the medical research company's stock after selling 54,097 shares during the quarter. Credit Agricole S A's holdings in Agilent Technologies were worth $12,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Agilent Technologies by 6.1% during the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after buying an additional 270 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Agilent Technologies by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,150,499 shares of the medical research company's stock valued at $154,562,000 after buying an additional 49,833 shares during the last quarter. TD Waterhouse Canada Inc. lifted its position in shares of Agilent Technologies by 48.7% during the 4th quarter. TD Waterhouse Canada Inc. now owns 443 shares of the medical research company's stock valued at $60,000 after buying an additional 145 shares during the last quarter. OneDigital Investment Advisors LLC lifted its position in shares of Agilent Technologies by 10.7% during the 4th quarter. OneDigital Investment Advisors LLC now owns 6,728 shares of the medical research company's stock valued at $904,000 after buying an additional 648 shares during the last quarter. Finally, IHT Wealth Management LLC lifted its position in shares of Agilent Technologies by 21.5% during the 4th quarter. IHT Wealth Management LLC now owns 1,919 shares of the medical research company's stock valued at $258,000 after buying an additional 339 shares during the last quarter. Institutional investors own 87.41% of the company's stock.

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.26% of the stock is currently owned by insiders.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock traded down $0.57 during trading on Tuesday, hitting $118.59. 362,687 shares of the stock traded hands, compared to its average volume of 1,933,362. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The stock has a market cap of $33.69 billion, a price-to-earnings ratio of 29.28, a PEG ratio of 3.69 and a beta of 1.22. The firm's fifty day moving average is $117.88 and its 200-day moving average is $116.87. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.26 by $0.05. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The company's revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.22 EPS. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. Research analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Leerink Partners increased their price objective on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a report on Friday, May 30th. Barclays increased their price objective on Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a report on Tuesday, June 24th. UBS Group dropped their price objective on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a report on Thursday, May 29th. Finally, TD Cowen increased their price objective on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies presently has an average rating of "Moderate Buy" and a consensus target price of $138.83.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.